{"nctId":"NCT00321984","briefTitle":"Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Gastroesophageal Reflux Disease","startDateStruct":{"date":"2006-06"},"conditions":["Gastroesophageal Reflux Disease"],"count":947,"armGroups":[{"label":"Dexlansoprazole MR 30 mg QD","type":"EXPERIMENTAL","interventionNames":["Drug: Dexlansoprazole MR"]},{"label":"Dexlansoprazole MR 60 mg QD","type":"EXPERIMENTAL","interventionNames":["Drug: Dexlansoprazole MR"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Dexlansoprazole MR","otherNames":["TAK-390MR","Kapidex","Dexilant"]},{"name":"Dexlansoprazole MR","otherNames":["TAK-390MR","Kapidex","Dexilant"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects identifying their main symptom as a burning feeling in the mid epigastric area and/or chest area (ie, heartburn).\n* Subject has a history of episodes of heartburn for 6 months or longer prior to Screening.\n* Subject must have a history of episodes of heartburn for 4 or more days during the 7 days prior to Day -1.\n\nExclusion Criteria:\n\n* Endoscopic Barrett's esophagus and/or definite dysplastic changes. History of dilatation of esophageal strictures.\n* Subjects with erosive esophagitis (EE) as shown by endoscopy.\n* Evidence of uncontrolled systemic disease. Co-existing diseases affecting the esophagus. Current or history of Zollinger-Ellison syndrome.\n* Subject has abnormal laboratory values.\n* Subjects with active gastric or duodenal ulcers within 4 weeks of the first dose.\n* Subject known to have acquired immunodeficiency syndrome (AIDS).\n* Known hypersensitivity to any proton pump inhibitor (PPI), any component of Dexlansoprazole MR, or antacid.\n* Use of prescription or non-prescription PPIs, histamine (H2) receptor antagonists, or sucralfate.\n* Chronic (\\>12 doses per month) use of nonsteroidal anti-inflammatory drugs (NSAIDs) or cyclo-oxygenase-2 (COX-2) inhibitors.\n* Use of antacids (except for study-supplied GelusilÂ® ).\n* Use of drugs with significant anticholinergic effects.\n* Subjects who cannot discontinue the use of misoprostol or prokinetics\n* Need for continuous anticoagulant therapy.\n* Females who are pregnant or lactating.\n* History of gastrointestinal surgery except for simple oversew of ulcer.\n* History of cancer within 3 years prior to screening.\n* Subject has participated in a previous Dexlansoprazole study.\n* Subjects who, in the opinion of the investigator, are unable to comply with the requirements of the study or are unsuitable for any reason.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Days With Neither Daytime Nor Nighttime Heartburn During Treatment as Assessed by Daily Electronic Diary-Median","description":"The percentage was calculated as the days that were heartburn-free out of the total number of days for which either a daytime or nighttime result was marked.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.5","spread":null},{"groupId":"OG001","value":"54.9","spread":null},{"groupId":"OG002","value":"50.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Days With Neither Daytime Nor Nighttime Heartburn During Treatment as Assessed by Daily Electronic Diary-Mean","description":"The percentage was calculated as the days that were heartburn-free out of the total number of days for which either a daytime or nighttime result was marked.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.0","spread":"25.6"},{"groupId":"OG001","value":"50.3","spread":"33.9"},{"groupId":"OG002","value":"49.1","spread":"34.7"}]}]}]},{"type":"SECONDARY","title":"Percentage of Days Without Nighttime Heartburn During Treatment as Assessed by Daily Electronic Diary-Median","description":"The percentage was calculated as the nights that were heartburn-free out of the total number of days for which a nighttime result was marked.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51.7","spread":null},{"groupId":"OG001","value":"80.8","spread":null},{"groupId":"OG002","value":"76.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Days Without Nighttime Heartburn During Treatment as Assessed by Daily Electronic Diary-Mean","description":"The percentage was calculated as the nights that were heartburn-free out of the total number of days for which a nighttime result was marked.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47.1","spread":"32.6"},{"groupId":"OG001","value":"67.6","spread":"34.1"},{"groupId":"OG002","value":"65.0","spread":"34.3"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1},"commonTop":["Diarrhoea (Excluding Infective)","Nausea and Vomiting Symptoms","Headaches NEC"]}}}